Talvey (talquetamab or talquetamab-tgvs) is a cancer medication used to treat multiple myeloma that has come back or doesn’t improve after at least four other treatments. As a bispecific antibody, it helps your immune system find and destroy cancer cells. It’s given as a shot under the skin either once a week or once every two weeks by a healthcare professional in a clinic or hospital. Common side effects include fever, changes in taste, nail problems, and a serious condition called cytokine release syndrome (CRS).
Talvey (talquetamab) is a bispecific T-cell engager (BiTE), which is a type of monoclonal antibody that’s designed to bind to two different targets.
One side of the antibody attaches to G protein–coupled receptor class C group 5 member D (GPRC5D), a protein on cancer cells (as well as other healthy cells in your body), while the other side binds to CD3, a protein on T-cells in your immune system. By connecting these two cells, Talvey (talquetamab) brings T-cells close to the cancer cells, helping the immune system attack and destroy the cancer cells.
The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.
Contact your healthcare provider immediately if you experience any of the following.
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
Talvey (talquetamab) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Talvey (talquetamab) can cause a serious reaction called cytokine release syndrome (CRS), which can be life-threatening. This happens when your immune system overreacts to the medication. Common symptoms include fever, low blood pressure, chills, trouble breathing, headache, and fast heart rate. In severe cases, CRS can lead to heart problems, lung problems, organ failure, or blood clotting problems.
CRS most often happens after step-up doses, which is why you need to stay in the hospital for two days after those doses so your care team can monitor you closely. To lower your risk, your care team will give you dexamethasone, diphenhydramine, and acetaminophen 1 to 3 hours before your step-up doses. Call your oncologist right away if you notice any signs of CRS. If CRS happens, your treatment might need to be paused or stopped depending on how severe it is.
Some people taking Talvey (talquetamab) developed nervous system problems. These can be mild, like numbness in the fingers or headache, or serious, like a condition called immune effector-cell associated neurotoxicity syndrome (ICANS). In clinical studies, most ICANS cases happened within 2 days after a dose and lasted around 2 days. Tell your care team immediately if you have symptoms like confusion, trouble speaking, shakiness, sleepiness, trouble writing, or seizures. ICANS can happen at the same time as CRS, after CRS, or on its own.
Since Talvey (talquetamab) can cause drowsiness or trouble staying alert, avoid driving or using heavy machinery during step-up dosing and for 2 days after. And if you develop new nervous system symptoms, wait until they go away before driving or operating machinery.
Talvey (talquetamab) might cause mouth problems such as dry mouth, changes in taste, difficulty swallowing, and mouth sores. These symptoms can develop at any time, but for most people they began within the first 15 days of treatment and took over a month to get better, though they didn’t fully go away for some people. Some people also experienced weight loss. In some cases, weight loss didn’t go away, even after treatment stopped.
Your oncologist will monitor your weight and check for mouth problems during treatment. If you notice mouth pain, trouble eating, or significant weight loss, tell your care team right away. They might recommend you meet with a dietician to help manage these problems.
Talvey (talquetamab) can cause serious infections, including bacterial infections and sepsis. Multiple myeloma already weakens your immune system, and Talvey (talquetamab) can lower it even more, making it harder for your body to fight infections. Your oncologist might prescribe antibiotics to help prevent infections. Contact your care team right away if you have any signs or symptoms of infection such as fever, body aches, chills, or cough.
Talvey (talquetamab) commonly causes low blood cell counts. Low white blood cells make it harder to fight infections and low platelets raise your risk of bleeding. If you have any unexplained bruising, blood in your urine, blood in your stool, or nosebleeds contact your care team right away. Your oncologist will check your blood counts regularly during treatment. If your blood cell levels drop too much, they might pause or stop Talvey (talquetamab).
Some people taking Talvey (talquetamab) developed skin reactions, including rash, redness, and irritation. These rashes are usually not severe, but you should still tell your oncologist if you notice any symptoms. In clinical trials, skin reactions typically started around 25 days after treatment began and took about a month to improve. If a severe rash develops, you might need to pause treatment until it gets better.
Talvey (talquetamab) can cause you to have high liver enzymes, which is a sign of liver irritation. Your oncologist will monitor your liver using blood tests, because most of the time you won’t notice any symptoms or feel differently when your liver is irritated. But if you do have sudden stomach pain, yellowing of the skin, or yellowing of the eyes, contact your care team right away. If your lab tests are abnormal, you might need to pause taking Talvey (talquetamab) while your oncologist looks into it.
Based on the way Talvey (talquetamab) works, it might cause harm to an unborn baby. If you’re able to get pregnant, use birth control while taking this medication and for 3 months after the last dose. Let your oncologist know if you’re pregnant or thinking about becoming pregnant while taking Talvey (talquetamab).
The recommended dose follows a step-up schedule. Each dose is given as an injection under the skin, starting with a low dose and increasing to the highest dose. The dose is based on your weight.
There are two schedule options:
Once a week
Once every two weeks
Prescription savings
Stop paying too much for your prescriptions. Compare prices, get pharmacy coupons, and save up to 80%.Health conditions
Medications & treatment
Access & affordability
Resources
No. Talvey isn’t considered chemotherapy because it works differently. Chemotherapy attacks any cell that grows very quickly, while Talvey is an immunotherapy. It only binds to certain proteins on cancer and immune cells, helping your immune system specifically attack the cancer cells.
Talvey is given as an injection under your skin by a healthcare professional at a clinic or hospital. It’s usually injected into your stomach, but it can also be given in your thigh or another area. You will receive it once a week or once every two weeks, depending on your treatment plan.
You need to stay in the hospital for two days after each step-up dose and your first full dose of Talvey. That’s because that’s when cytokine release syndrome (CRS) and nervous system problems are most likely to happen. It’s safest for you to be closely monitored in the hospital during these doses. But, once you’ve completed step-up dosing and are receiving your regular weekly or biweekly doses, you won’t need to stay in the hospital.
Yes. Talvey is FDA approved under accelerated approval to treat multiple myeloma in adults who've already tried at least four other therapies. This means the FDA approved it faster than usual because the medication showed promising results in treating multiple myeloma that didn’t respond to other treatments. Since Talvey was approved based on early study results, the FDA requires more research to confirm that it works as expected.